55 withdrawn. 55 Phase 2, 9 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Withdrawn 55 |
| Phase 1 | 9 | Withdrawn 9 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA Romiplostim N01 - Aplastic Anemia | Phase 2 | Withdrawn | Peking Union Medical College Hospital | 2026-06-01 | 2026-06-04 | |
| CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA Cyclosporine (CsA), Thrombopoietin Receptor Agonist, Romiplostim N01 - Severe Aplastic Anemia (SAA), Transfusion-dependent Non-severe Aplastic Anemia | Phase 2 | Withdrawn | Peking Union Medical College Hospital | 2026-06-01 | 2026-06-04 | |
| A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy Mitapivat - Sickle Cell Disease, Nephropathy | Phase 2 | Withdrawn | Agios Pharmaceuticals, Inc. | 2026-03-01 | 2026-04-03 | |
| Biotin-Acridine Red Cell Exchange Kinetics Pathogen reduced red blood cells - Sickle Cell Disease | Phase 2 | Withdrawn | Cerus Corporation | 2025-10-15 | 2026-09-22 | |
| 177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia 177Lu-PSMA-617 - Metastatic Castration Resistant Prostate Cancer, Cytopenia | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-08-03 | 2026-05-08 | |
| Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma Iron dextran 1000 mg IV - Anemia, Iron Deficiency, Melanoma | Phase 2 | Withdrawn | Indiana University | 2025-05-01 | 2025-07-09 | |
| UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia Romiplostim, Immunosuppressive therapy (IST) - Aplastic Anemia | Phase 2 | Withdrawn | Anjali Sharathkumar | 2025-04-10 | 2026-10-16 | |
| Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms ASTX029, ASTX727 - Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-01-31 | 2026-02-13 | |
| Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS Magrolimab, 7+3, CPX-351 - Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Phase 2 | Withdrawn | Uwe Platzbecker | 2024-03-31 | 2024-02-12 | |
| A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia). KER-047 - Iron Deficiency Anemia | Phase 2 | Withdrawn | Keros Therapeutics, Inc. | 2023-11-30 | 2023-11-24 | |
| Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy Romiplostim, Antithymocyte Globulin, Cyclosporine A - Severe Aplastic Anemia (SAA) | Phase 2 | Withdrawn | Amgen | 2023-08-31 | 2023-09-29 | |
| Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Crohn's Disease Investigational Product, Placebo - Crohn Disease | Phase 2 | Withdrawn | Telavant, Inc. | 2023-07-30 | 2023-10-19 | |
| A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia FP-045 - Fanconi Anemia | Phase 1 / Phase 2 | Withdrawn | Foresee Pharmaceuticals Co., Ltd. | 2023-06-30 | 2025-03-06 | |
| Peripheral Blood Stem Cell Collection From Patients With Sickle Cell Disease (SCD) Using Plerixafor Plerixafor - Sickle Cell Disease | Phase 2 | Withdrawn | St. Jude Children's Research Hospital | 2023-04-01 | 2023-04-07 | |
| Safety, Tolerability, PK and PD of Intravenous Ferric Carboxymaltose in Infants With Iron Deficiency Anemia Ferric carboxymaltose - Iron Deficiency, Anaemia | Phase 2 | Withdrawn | American Regent, Inc. | 2022-07-21 | 2023-01-06 | |
| Study to Evaluate Efficacy and Safety of BGE-117 in Moderately to Severely Anemic Older Individuals After Major Hip Surgery BGE-117, 4mg, Ferrous Sulfate, Matching Placebo - Acute Posthemorrhagic Anemia | Phase 2 | Withdrawn | BioAge Labs, Inc. | 2022-04-01 | 2022-05-05 | |
| Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia Hetrombopag - Aplastic Anemia, Drug Effect | Phase 2 / Phase 3 | Withdrawn | Peking Union Medical College Hospital | 2021-10-01 | 2026-06-08 | |
| Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID - Beta-Thalassemia | Phase 2 | Withdrawn | Vifor (International) Inc. | 2021-09-20 | 2022-11-10 | |
| Iron Sucrose in Patients With Iron Deficiency and POTS Sucrose, Placebo, Tilt Table Test - Iron-deficiency, Postural Orthostatic Tachycardia Syndrome | Phase 2 | Withdrawn | Mayo Clinic | 2021-04-01 | 2023-06-13 | |
| Study to Evaluate Efficacy and Safety of BGE-117 in the Treatment of Anemia of Aging BGE-117, Placebo - Anemia | Phase 2 | Withdrawn | BioAge Labs, Inc. | 2021-03-22 | 2022-05-05 |
Showing 20 of 55. Sign in to see all of them.
Anemia, Sickle Cell (17) · Anemia, Refractory, with Excess of Blasts (7) · Myelodysplastic Syndromes (7) · Anemia, Aplastic (6) · Leukemia, Myeloid, Acute (6) · Anemia, Iron-Deficiency (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Leukemia (4) · Myeloproliferative Disorders (4) · Thalassemia (4) · beta-Thalassemia (4) · Congenital Abnormalities (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myeloid, Accelerated Phase (3)
Hemic and Lymphatic Diseases (55) · Hematologic Diseases (54) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (27) · Anemia, Hemolytic (26) · Genetic Diseases, Inborn (24) · Anemia, Hemolytic, Congenital (23) · Hemoglobinopathies (22) · Bone Marrow Diseases (19) · Nutritional and Metabolic Diseases (9) · Pathologic Processes (9) · Pathological Conditions, Signs and Symptoms (9) · Immune System Diseases (8) · Metabolic Diseases (8) · Neoplasms by Histologic Type (8)
Cyclosporine (4) · Epoetin Alfa (3) · Peripheral Blood Stem Cell Transplantation (3) · Busulfan (2) · Cyclophosphamide (2) · Deferasirox (2) · Ferric Oxide, Saccharated (2) · Methotrexate (2) · Whole-Body Irradiation (2) · ferrous sulfate (2) · fludarabine phosphate (2) · romiplostim (2) · ASTX029 (1) · Abciximab (1) · Analgesia, Patient-Controlled (1)
Peking Union Medical College Hospital (3) · BioAge Labs, Inc. (2) · Johns Hopkins University (2) · M.D. Anderson Cancer Center (2) · Masonic Cancer Center, University of Minnesota (2) · Abfero Pharmaceuticals, Inc (1) · Agios Pharmaceuticals, Inc. (1) · Alnylam Pharmaceuticals (1) · American Regent, Inc. (1) · Amgen (1) · Anjali Sharathkumar (1) · Cerus Corporation (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's National Research Institute (1) · Denver Health and Hospital Authority (1)
United States (25) · Australia (4) · Israel (3) · Belgium (2) · Canada (2) · France (2) · Italy (2) · Lebanon (2) · Netherlands (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Austria (1) · Bahrain (1) · Bosnia and Herzegovina (1) · Brazil (1)
Akshay Sharma, MBBS (1) · Ali Taher, MD, PhD (1) · Anjali Sharathkumar, MD (1) · Arthur L. Burnett, MD (1) · Bagi Jana, MD (1) · Bing Han, Master (1) · Claudio Brunstein, MD, PhD (1) · Daniel B Kim-Shapiro, PhD (1) · Fredric M Pieracci, MD, MPH (1) · Gary Swergold, MD, PhD (1) · Goetz H Kloecker, MD (1) · Guillermo Montalban Bravo (1) · Heinz Zwierzina, MD (1) · Jeffrey Zwicker, MD (1) · John D Roberts, M.D. (1)
2018 (1), 2023 (1), P30CA036727 (1), R01HL079915 (1), R37HL058091 (1), U54HL070871 (1)